Loading...
•
Sep 30, 2022
Tonix Q3 2022 Earnings Report
Tonix reported financial results for the third quarter ended September 30, 2022 and provided an overview of recent operational highlights.
Key Takeaways
Tonix Pharmaceuticals reported a net loss of $29.0 million, or $0.69 per share, for the third quarter ended September 30, 2022. The company's cash and cash equivalents totaled approximately $140 million as of September 30, 2022. Tonix is advancing multiple programs within its pipeline, with several Phase 2 or 3 studies expected to be in the clinic by the first quarter of 2023.
Cash and cash equivalents totaled approximately $140 million at September 30, 2022.
A confirmatory Phase 3 study for fibromyalgia and a potentially pivotal Phase 2 study for Long COVID have commenced.
Interim data from TNX-102 SL studies in Fibromyalgia and Long COVID are expected in the second quarter of 2023.
Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. are operational.
Forward Guidance
Tonix expects R&D expenses to increase throughout the remainder of 2022 as it moves its clinical development programs forward and invests in its development pipeline.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...